{"name": "", "children": [{"name": "2016 ALLERGAN", "children": []}, {"name": "SUSTAINABILITY PERFORMANCE REPORT", "children": [{"name": "3", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}, {"name": "Allergan plc is a bold, global pharmaceutical company focused on innovation and bringing to market t", "children": []}, {"name": "We are mindful of our impact on the world around us. Allergan has a deep commitment to the health, s", "children": []}, {"name": "As a company, we\u2019ve set an ambitious goal to further reduce our sustainability impact 20% by 2020 (o", "children": []}, {"name": "Allergan remains focused on sustainable business practices including:", "children": []}, {"name": "Offering needed products that have environmental health and safety design considerations,", "children": []}, {"name": "Managing our environmental impact by improving energy, waste, and water efficiency,", "children": []}, {"name": "Providing a safe and healthy workplace for our employees,", "children": []}, {"name": "Working with our supply chains to improve corporate responsibility performance, and", "children": []}, {"name": "Executing on the principals of our Social Contract with our patients.", "children": []}, {"name": "More information about areas of our commitment is provided throughout the Responsibility section of ", "children": []}, {"name": "Allergan is committed to sustainable business values. We work to keep these values in mind in all as", "children": []}, {"name": "Brent Saunders", "children": []}, {"name": "Chairman, President & CEO Allergan, Plc", "children": []}, {"name": "A MESSAGE FROM BRENT SAUNDERS, CHAIRMAN, PRESIDENT & CEO", "children": [{"name": "3", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}, {"name": "4", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}, {"name": "Reporting includes economic, governance and social parameters as well as environmental health and sa", "children": []}, {"name": "2015 proved to be another successful year for Allergan\u2019s sustainability program. Allergan\u2019s specific", "children": []}, {"name": "the 2015 goals is described in the Strategic Performance Goals & Results. Our goals were achieved wh", "children": []}, {"name": "completed the integration of Allergan Inc, and Actavis, plc.", "children": []}, {"name": "In summary, comparing 2015 with 2014, Allergan achieved the following", "children": [{"name": "1", "children": []}, {"name": "1. Comparison of 2014 Allergan, plc vs 2015 Allergan, plc manufacturing and R&D operations. Excludin", "children": []}]}]}, {"name": "INTRODUCTION", "children": [{"name": "The occupational injury and illness frequency rate improved by over 35% to 0.49.", "children": [{"name": "2", "children": []}]}, {"name": "Recycling reached a rate of more than 80% of total nonhazardous waste generated.", "children": []}, {"name": "Total energy consumption increased by 1% for current sites but this equates to a decrease of 7% year", "children": []}, {"name": "Total Greenhouse Gas emissions increased by 4% for current sites, but likewise, this equates to a de", "children": []}, {"name": "Total water consumption decreased by 4% for current sites but this equates to a decrease of 11% year", "children": [{"name": "5", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}, {"name": "SUSTAINABILITY PROGRAM AND REPORTING SCOPE, LIMITATIONS AND PROCESSES", "children": [{"name": "Scope", "children": [{"name": "Allergan\u2019s sustainability program involves the business/economic, social and environmental aspects a", "children": []}, {"name": "Changes in scope occur when Allergan acquires new products, processes or businesses which have occur", "children": []}]}, {"name": "Limitations", "children": [{"name": "Allergan is including owned or leased locations worldwide in its responses and summaries along with ", "children": []}, {"name": "Previously reported data for 2014 have been adjusted to include Actavis, plc operations that have re", "children": []}]}, {"name": "Data Capture and Verification", "children": [{"name": "Economic data is captured through various systems and the methodology for capture and management of ", "children": []}]}, {"name": "Reporting Cycles", "children": [{"name": "Generally, reporting of environmental, health and safety data is conducted internally on a monthly b", "children": []}]}, {"name": "Report Contact", "children": [{"name": "Direct all inquiries to", "children": []}, {"name": "corporate.communications@allergan.com", "children": []}]}, {"name": "Report Content Process", "children": [{"name": "Allergan generates various reports for economic, social and environmental purposes. These reports ar", "children": [{"name": "6", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}]}]}, {"name": "SUSTAINABILITY STRUCTURE AND REPORTING RELATIONSHIPS", "children": [{"name": "Allergan EHS and Sustainability Steering Committee", "children": [{"name": "Allergan has established an Environmental, Health and Safety (EHS) Steering Committee with represent", "children": []}]}, {"name": "Sustainability Structure and Relationships", "children": [{"name": "Allergan\u2019s SVP of EHS and Engineering reports to the Executive Committee through the SVP Global Oper", "children": []}, {"name": "Each manufacturing and R&D facility has an EHS staff that manages sustainability initiatives as well", "children": []}, {"name": "Economic and social sustainability initiatives and activities are managed by several groups dependin", "children": []}]}]}, {"name": "ALLERGAN AND THE PRECAUTIONARY PRINCIPLE", "children": [{"name": "Allergan has always practiced the Precautionary Principle with regard to its products and operations", "children": [{"name": "7", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}]}, {"name": "2011\u20132015 ALLERGAN STRATEGIC PERFORMANCE GOALS & RESULTS", "children": [{"name": "In our pursuit of continual improvement we have established 2020 goals to further reduce our sustain", "children": []}]}, {"name": "EHS REGULATORY COMPLIANCE", "children": [{"name": "Allergan did not receive any penalties or fines in 2015. Our San Jose site did receive a notice of v", "children": []}, {"name": "OBJECTIVE", "children": []}, {"name": "GOAL 2010 vs 2015 RESULTS", "children": [{"name": "Injuries and Illness Incident rate below 0.80 0.49\tRecycling Recycle > 75% of waste\t83% Recycling ra", "children": []}, {"name": "Reduce our employee injury rate by 10% every year from 2016 to 2020 (as defined by ASTM E2920 \u2013 14: ", "children": []}, {"name": "Reduce energy and fuel consumption by 20% compared to 2015.", "children": []}, {"name": "Reduce greenhouse gas emissions by 20% compared to 2015 (aligned with the Science Based Targets appr", "children": []}, {"name": "Reduce water consumption in operations located in extreme water scarcity risk regions by 20% compare", "children": []}, {"name": "Reduce total waste generated by 20% compared to 2015.", "children": []}, {"name": "Eliminate waste to landfill from manufacturing operations.", "children": []}]}]}, {"name": "ALLERGAN\u2019S 2020 GOALS", "children": [{"name": "8", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}, {"name": "MANAGEMENT SYSTEMS", "children": [{"name": "Allergan has developed an internal Environmental, Health and Safety Management System (EHSMS). We co", "children": []}]}, {"name": "RISK ASSESSMENT PROCESS", "children": [{"name": "Proactively identifying potential workplace environmental, health, and safety risks is a critical pa", "children": []}]}, {"name": "CORRECTIVE ACTION PROCESS", "children": [{"name": "Allergan has established a robust process for identifying and correcting hazards. The process is fac", "children": [{"name": "2011 2012 2013 2014 2015\tNumber of Risk Assessments 109 264 153 161 246\tCorrective Actions/ Preventi", "children": []}]}, {"name": "POTENTIAL RISK ASSESSMENT", "children": [{"name": "Severity /Impact", "children": []}, {"name": "Probability/Likelihood", "children": [{"name": "0", "children": []}, {"name": "5", "children": []}, {"name": "10", "children": []}, {"name": "20", "children": []}, {"name": "50", "children": []}, {"name": "4 3 2", "children": []}, {"name": "1", "children": []}, {"name": "5", "children": []}, {"name": "6", "children": []}, {"name": "1. Process Safety 2. Fleet Safety 3. Forklift 4. Electricity 5. Fall from Height 6. Overexposure", "children": [{"name": "9", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}]}]}]}, {"name": "ALLERGAN\u2019S EHS AUDIT PROGRAM", "children": [{"name": "Allergan has a comprehensive program in place for conducting environmental, health and safety audits", "children": []}, {"name": "Through the EHS audit program Allergan has been able to minimize the EHS risks at its facilities, an", "children": []}]}, {"name": "SUSTAINABLE SUPPLY CHAINS", "children": [{"name": "Sustainable Supply Chain Projects", "children": [{"name": "We understand that our sustainability impact not only includes Allergan\u2019s operations but also the ac", "children": []}, {"name": "We also continue to actively participate in the Pharmaceutical Supply Chain Initiative (PSCI). This ", "children": []}]}, {"name": "California Transparency in Supply Chains Act of 2010", "children": [{"name": "The California Transparency in Supply Chains Act of 2010 is intended to provide public information f", "children": []}, {"name": "Allergan is committed to conducting business only with suppliers who adhere to the highest ethical s", "children": []}]}, {"name": "Supplier Assessments and Qualification", "children": [{"name": "Prior to engagement of a supplier, Allergan evaluates the supplier through a risk-based assessment. ", "children": []}]}, {"name": "Supplier Performance Reviews", "children": [{"name": "Allergan is committed to continuous improvement in its supply chain. Allergan and its suppliers moni", "children": []}]}, {"name": "Supplier Audits", "children": [{"name": "Allergan also regularly audits key suppliers to confirm compliance with supplier performance and qua", "children": [{"name": "10", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}]}]}, {"name": "INNOVATION", "children": [{"name": "Allergan\u2019s world-class research and development (R&D) program embodies our efforts to bring the best", "children": []}, {"name": "Our commitment to R&D has been evident since the 1950\u2019s, when we began pioneering new treatments to ", "children": []}, {"name": "Since Allergan\u2019s founding, the ability to build bridges \u2013 with our customers and with each other \u2013 h", "children": []}, {"name": "Our R&D organization is structured into integrated teams that focus on discovery for different drug ", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}, {"name": "Supplier Agreements", "children": [{"name": "Allergan has supply agreements, quality agreements and/or purchase order terms and conditions with a", "children": []}]}, {"name": "Employee Training and Compliance", "children": [{"name": "All Allergan employees are required to comply with Allergan\u2019s Code of Business Conduct and Ethics. A", "children": [{"name": "11", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}]}]}, {"name": "IMPACTS, MATERIALITY, RISKS AND OPPORTUNITIES", "children": [{"name": "Based on internal analysis of risk and opportunities, the following figure represents Allergan\u2019s vie", "children": []}]}, {"name": "STAKEHOLDER ENGAGEMENT AND COLLABORATIONS", "children": [{"name": "Allergan\u2019s view of stakeholders is very broad, encompassing patients, doctors, employees, shareholde", "children": [{"name": "Hazardous Materials & Chemical Management", "children": []}]}, {"name": "SUSTAINABILITY AREAS OF RISK OPPORTUNITY", "children": [{"name": "Perceived Importance to Stakeholders", "children": []}, {"name": "High", "children": [{"name": "Perceived Influence on Our Business", "children": [{"name": "Auditing & Verification", "children": []}, {"name": "Biodiversity", "children": []}, {"name": "Environmental Remediation", "children": []}, {"name": "Employee Diversity", "children": []}, {"name": "Stakeholder Engagement & Collaborations", "children": []}, {"name": "Product Safety Ethical Practices", "children": []}, {"name": "Recycling", "children": []}, {"name": "Human Rights Community Interaction", "children": []}, {"name": "Management Employee Health & Safety", "children": []}, {"name": "Waste & Water Management Employee Engagement", "children": []}, {"name": "Supply Chain Management", "children": []}]}, {"name": "early-stage exploration to human clinical testing, for a much broader perspective. Additionally, met", "children": [{"name": "12", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}, {"name": "Allergan has had a long history of addressing climate change through development and implementation ", "children": []}, {"name": "year. Our Waco, TX, and Cincinnati, OH facilities were selected as Energy Star Plants. The award rec", "children": []}, {"name": "All our R&D and manufacturing facilities have site targets regarding energy consumption reductions a", "children": []}, {"name": "The 2015 overall GHG emissions for Allergan manufacturing and R&D operations are presented in the fo", "children": [{"name": "Scope 1 - R&D / Manufacturing Greenhouse Gas Emissions (MTCO2E) - Direct from Fuel Combustion", "children": []}, {"name": "Scope 2 - Manufacturing Greenhouse Gas Emissions (MTCO2E) - Indirect from Electrical Consumption", "children": []}, {"name": "Total Greenhouse Gas Emissions per Sales (MTCO2E/$million)", "children": [{"name": "2010 2011 2012 2013 2014 2015", "children": []}]}]}]}, {"name": "CLIMATE CHANGE - GREENHOUSE GAS EMISSIONS", "children": [{"name": "0", "children": []}, {"name": "20,000", "children": []}, {"name": "40,000", "children": []}, {"name": "60,000", "children": []}, {"name": "80,000", "children": []}, {"name": "100,000", "children": []}, {"name": "120,000", "children": []}, {"name": "0", "children": []}, {"name": "2", "children": []}, {"name": "4", "children": []}, {"name": "6", "children": []}, {"name": "8", "children": []}, {"name": "10", "children": []}, {"name": "12", "children": []}, {"name": "14", "children": []}, {"name": "16", "children": []}, {"name": "Greenhouse Emissions (MT CO2E)", "children": []}]}]}, {"name": ".................", "children": []}, {"name": "...........", "children": [{"name": "......................", "children": []}, {"name": "..........", "children": [{"name": "23,423 50,234 24,536 48,173 24,659 48,212", "children": []}, {"name": "33,808 63,178", "children": []}, {"name": "32,443 68,444", "children": []}, {"name": "25,244 49,367", "children": []}, {"name": "13", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}, {"name": "Supply Chain", "children": [{"name": "During the past four years Allergan has begun an initiative to gain a better understanding of the gr", "children": []}]}]}]}]}, {"name": "WASTE MANAGEMENT AND RECYCLING", "children": [{"name": "Hazardous Waste Trends", "children": [{"name": "We achieved a 59% reduction in the intensity of hazardous waste generation (metric tonnes/sales) in ", "children": [{"name": "2010 2011 2012 2013 2014 2015", "children": []}]}, {"name": "CLIMATE CHANGE - TOTAL ENERGY CONSUMPTION", "children": [{"name": "50", "children": []}, {"name": "100", "children": []}, {"name": "150", "children": []}, {"name": "200", "children": []}, {"name": "250", "children": []}, {"name": "Total Energy Consumption ( GJ)", "children": [{"name": "1,340,000", "children": []}, {"name": "1,290,000", "children": []}, {"name": "1,240,000", "children": []}, {"name": "1,190,000", "children": []}, {"name": "1,140,000", "children": []}, {"name": "1,090,000", "children": []}, {"name": "1,040,000", "children": []}, {"name": "990,000", "children": []}, {"name": "940,000 0", "children": []}, {"name": "944,028 969,645 987,978 1,019,807", "children": []}, {"name": "1,298,832 1,311,256", "children": []}, {"name": "Total Energy Consumption (GJ)", "children": []}, {"name": "Total Energy per Sales (GJ/millions)", "children": [{"name": "2010 2011 2012 2013 2014 2015", "children": []}]}, {"name": "0.0", "children": []}, {"name": "0.0", "children": []}, {"name": "0.1", "children": []}, {"name": "0.1", "children": []}, {"name": "0.1", "children": []}]}, {"name": "Total Energy Consumption ( GJ)", "children": [{"name": "700", "children": []}, {"name": "600", "children": []}, {"name": "500", "children": []}, {"name": "400", "children": []}, {"name": "300", "children": []}, {"name": "200", "children": []}, {"name": "100", "children": []}, {"name": "0 0.0", "children": []}, {"name": "800", "children": []}, {"name": "0.1", "children": []}]}]}, {"name": "HAZARDOUS WASTE GENERATED", "children": [{"name": "Hazardous Waste (tonnes)", "children": []}, {"name": "HW per Sales (tonnes/million sales)", "children": []}]}]}, {"name": "Energy Management", "children": [{"name": "Allergan set an aggressive goal to reduce energy consumption by 15% by 2015 using 2010 as the baseli", "children": [{"name": "14", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}]}, {"name": "Nonhazardous Waste Trends", "children": [{"name": "We achieved a 60% reduction in the intensity of non-hazardous waste generation (metric tonnes/sales)", "children": []}, {"name": "Several of our locations send zero waste to the landfill. Nonhazardous waste reduction is accomplish", "children": []}]}]}, {"name": "WATER MANAGEMENT", "children": [{"name": "Water is an important resource for our operations. Our ophthalmic products are primarily composed of", "children": []}, {"name": "We achieved a 63% reduction in water withdrawal intensity (metric tonnes/sales) in 2015 compared to ", "children": [{"name": "2010 2011 2012 2013 2014 2015", "children": []}, {"name": "0.1", "children": []}, {"name": "0.1", "children": []}, {"name": "0.2", "children": []}, {"name": "0.2", "children": []}, {"name": "0.3", "children": []}, {"name": "Solid Waste (MT)", "children": [{"name": "1,400", "children": []}, {"name": "1,200", "children": []}, {"name": "1,000", "children": []}, {"name": "800", "children": []}, {"name": "600", "children": []}, {"name": "400", "children": []}, {"name": "200", "children": []}, {"name": "0 0.0", "children": []}, {"name": "0.3", "children": []}, {"name": "0.4 1,600", "children": []}]}]}, {"name": "SOLID WASTE GENERATED", "children": [{"name": "Solid Waste (tonnes)", "children": []}, {"name": "SW per Sales (tonnes/million sales)", "children": [{"name": "2010 2011 2012 2013 2014 2015", "children": []}, {"name": "68.00", "children": []}, {"name": "70.00", "children": []}, {"name": "74.00", "children": []}, {"name": "76.00", "children": []}, {"name": "80.00", "children": []}]}, {"name": "Waste Recycled (MT)", "children": [{"name": "6,000", "children": []}, {"name": "5,000", "children": []}, {"name": "4,000", "children": []}, {"name": "3,000", "children": []}, {"name": "2,000", "children": []}, {"name": "1,000", "children": []}, {"name": "0 66.0", "children": []}, {"name": "78.00", "children": []}, {"name": "82.00", "children": []}, {"name": "84.00", "children": []}, {"name": "74.00", "children": []}]}]}, {"name": "WASTE RECYCLED", "children": [{"name": "Recycling (tonnes)", "children": [{"name": "15", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}, {"name": "Water Consumption (M3)", "children": [{"name": "2010 2011 2012 2013 2014 2015", "children": []}, {"name": "40", "children": []}, {"name": "60", "children": []}, {"name": "100", "children": []}, {"name": "120", "children": []}, {"name": "160", "children": []}, {"name": "1,200,000", "children": []}, {"name": "1,000,000", "children": []}, {"name": "800,000", "children": []}, {"name": "600,000", "children": []}, {"name": "400,000", "children": []}, {"name": "200,000", "children": []}, {"name": "0 0", "children": []}, {"name": "140", "children": []}, {"name": "180", "children": []}, {"name": "200", "children": []}, {"name": "80", "children": []}, {"name": "20", "children": []}]}]}, {"name": "WATER CONSUMPTION", "children": [{"name": "Water (M3)", "children": []}, {"name": "Water per Sales (M3 million sales)", "children": []}, {"name": "withdrawal during this same time frame increased by 14% due to acquisitions. During this time we hav", "children": []}]}]}, {"name": "WASTE WATER DISCHARGE INDICATORS", "children": [{"name": "We regularly monitor wastewater discharge from our operating locations to ensure compliance with reg", "children": []}, {"name": "Chemical Oxygen Demand Trend", "children": [{"name": "Chemical Oxygen Demand (COD), a measure of oxygen demanding chemicals in wastewater, has been reduce", "children": []}]}, {"name": "Biochemical Oxygen Demand Trend", "children": [{"name": "Biochemical Oxygen Demand (BOD), a measure of oxygen demand through biochemical processes in wastewa", "children": []}, {"name": "significantly due to wastewater equalization and neutralization facilities at applicable manufacturi", "children": []}]}, {"name": "Total Suspended Solids Trend", "children": [{"name": "Total Suspended Solids (TSS) in wastewater discharges from Allergan facilities have been reduced sig", "children": []}, {"name": "We regularly monitor relevant permitted air emissions from our operating locations to ensure complia", "children": []}]}]}, {"name": "AIR EMISSIONS INDICATORS", "children": [{"name": "Volatile Organic Carbon Emissions", "children": [{"name": "Allergan is currently in compliance with all regulatory requirements regarding air emissions at its ", "children": []}]}, {"name": "Nitrogen Oxide (NOx) Emissions", "children": [{"name": "Allergan has negligible nitrogen oxide emissions from its facilities. These emissions are associated", "children": [{"name": "16", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}]}]}, {"name": "USE OF MERCURIAL PRESERVATIVES", "children": [{"name": "We have significantly reduced the use of mercurial preservatives (Thimerosal, Phenylmercuric Acetate", "children": []}]}, {"name": "ALLERGAN EHS PRODUCT DESIGN", "children": [{"name": "In 2015 we started to integrate Allergan, Inc.\u2019s Environmental, Health and Safety Product Design Cri", "children": []}, {"name": "Allergan continues our top quartile safety performance as measured by the number of injuries/illness", "children": []}, {"name": "Increasing awareness around Critical Safety Risks. Our Critical Safety Rules program focuses on 8 ri", "children": []}, {"name": "Implementation of Human and Organizational Performance (HOP) concepts and training.", "children": []}, {"name": "Encouraging employees to identify EHS risks through our Good Observations program. In 2015, over 65%", "children": []}, {"name": "Management conducting weekly Leadership Inspections (EHS Gemba Walks).", "children": []}, {"name": "Issuing EHS Alerts to share information on significant incidents.", "children": []}, {"name": "Forming learning teams to develop a deeper understanding of systemic failures associated with seriou", "children": [{"name": "2010 2011 2012 2013 2014 2015", "children": []}, {"name": "Occupational Injury and Illness Incident Frequency Rate (cases per 200,000 hours worked)", "children": []}]}, {"name": "KEEPING EMPLOYEES SAFE", "children": [{"name": "0.49", "children": []}, {"name": "0.50 0.57", "children": []}, {"name": "0.71", "children": []}, {"name": "0.98", "children": []}, {"name": "0.90", "children": []}, {"name": "We have implemented several programs to proactively identify workplace hazards and reduce employee i", "children": []}]}]}, {"name": "KEEPING EMPLOYEES AND CONTRACTORS SAFE", "children": [{"name": "Increasing employee awareness around workplace hazards and incidents. For example, one Allergan loca", "children": [{"name": "17", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}, {"name": "CRITICAL SAFETY RULES", "children": [{"name": "Process Safety\tWhen processing flammable solvents and/or combustible dusts do so only in appropriate", "children": []}]}, {"name": "CRITICAL SAFETY RULES", "children": []}, {"name": "CRITICAL SAFETY RULES", "children": [{"name": "Do not enter/immediately evacuate an area where the atmosphere is dangerous to life and health (i.e.", "children": []}, {"name": "17%", "children": [{"name": "HAND LACERATIONS", "children": []}]}, {"name": "21%", "children": [{"name": "SLIPS/TRIPS/FALLS", "children": []}]}, {"name": "4%", "children": [{"name": "EYE INJURIES", "children": []}]}, {"name": "21%", "children": [{"name": "SUB MUSULO-SKELETAL", "children": []}]}, {"name": "11%", "children": [{"name": "ACUTE MUSULO-SKELETAL", "children": []}]}, {"name": "3%", "children": [{"name": "API EXPOSURE", "children": []}]}, {"name": "6%", "children": [{"name": "STRUCK BY OBJECT/VEHICLE", "children": []}]}, {"name": "2%", "children": [{"name": "FALL FROM HEIGHT", "children": []}]}, {"name": "8%", "children": [{"name": "OTHER", "children": []}]}, {"name": "7%", "children": [{"name": "CAR ACCIDENT", "children": []}]}]}, {"name": "INCIDENT TYPES", "children": []}, {"name": "CRITICAL SAFETY RULES", "children": [{"name": "18", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}]}, {"name": "DIVERSITY, TRAINING, DEVELOPMENT AND RECOGNITION", "children": [{"name": "The strength of our organization rests upon our more than 16,000 diverse, talented and committed emp", "children": []}, {"name": "Learning & Development", "children": [{"name": "Allergan is committed to being an inclusive and developmentally rewarding place to work. Our lean an", "children": [{"name": "0%", "children": []}, {"name": "20%", "children": []}, {"name": "40%", "children": []}, {"name": "60%", "children": []}, {"name": "80%", "children": []}, {"name": "100%", "children": [{"name": ".........................................................", "children": []}, {"name": ".........................................................", "children": []}, {"name": ".........................................................", "children": []}, {"name": ".........................................................", "children": []}, {"name": ".........................................................", "children": []}, {"name": ".........................................................", "children": []}, {"name": ".........................................................", "children": []}, {"name": ".........................................................", "children": []}, {"name": ".........................................................", "children": []}, {"name": ".........................................................", "children": []}]}, {"name": "Asia Paci\ufb01c", "children": []}, {"name": "EM EA Latin America", "children": []}, {"name": "North America", "children": [{"name": "Asia Paci\ufb01c", "children": []}, {"name": "EM EA Latin America", "children": []}, {"name": "North America", "children": []}]}, {"name": "0%", "children": []}, {"name": "20%", "children": []}, {"name": "40%", "children": []}, {"name": "60%", "children": []}, {"name": "80%", "children": []}, {"name": "100%", "children": [{"name": ".........................................................", "children": []}, {"name": ".........................................................", "children": []}, {"name": ".........................................................", "children": []}, {"name": ".........................................................", "children": []}, {"name": ".........................................................", "children": []}]}, {"name": "Asia Paci\ufb01c", "children": []}, {"name": "EM EA Latin America", "children": []}, {"name": "North America", "children": []}]}, {"name": "<1", "children": []}, {"name": "1\u20133", "children": []}, {"name": "3\u20137", "children": []}, {"name": "7\u201315", "children": []}, {"name": ">15", "children": []}, {"name": "FEMALE", "children": []}, {"name": "MALE", "children": []}, {"name": "<25", "children": []}, {"name": "25\u201335", "children": []}, {"name": "35\u201345", "children": []}, {"name": "45\u201355", "children": []}, {"name": ">55", "children": []}]}, {"name": "ALLERGAN DISTRIBUTION BY REGION", "children": []}, {"name": "TENURE GENDER AGE", "children": [{"name": "19", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}]}, {"name": "BIOETHICS", "children": [{"name": "Allergan is committed to strong bioethical practices. When working with biological agents, organisms", "children": []}, {"name": "Allergan meets Center for Disease Control (CDC) requirements and is licensed by the CDC to manage bi", "children": []}]}, {"name": "CORPORATE STATEMENT ON ANIMAL TESTING", "children": [{"name": "The U.S. Food and Drug Administration (FDA) and other worldwide health regulatory agencies currently", "children": []}, {"name": "When animal work is necessary it is designed to ensure the highest standards of animal welfare and u", "children": []}, {"name": "Allergan shares the pharmaceutical industry\u2019s goal of reducing or eliminating animal testing whereve", "children": []}, {"name": "TENURE", "children": [{"name": "11% 16%", "children": []}, {"name": "24% 24%", "children": []}, {"name": "25%", "children": []}]}, {"name": "GENDER", "children": [{"name": "48% 52%", "children": []}, {"name": "33%", "children": []}, {"name": "36%", "children": []}, {"name": "21%", "children": []}, {"name": "7% 3%", "children": []}]}, {"name": "ALLERGAN DISTRIBUTION", "children": [{"name": "20", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}]}, {"name": "PHILANTHROPY AND CITIZENSHIP", "children": [{"name": "The Allergan Foundation (TAF) has made grants focusing support in four philanthropic areas: the arts", "children": []}, {"name": "Priority 1", "children": [{"name": "is to support local health and human services efforts through donations and grants as well as throug", "children": []}]}, {"name": "Priority 2", "children": [{"name": "is to support local educational programs and services through donations and grants as well as throug", "children": []}]}, {"name": "Priority 3", "children": [{"name": "is to support local arts and arts and civic programs and services through donations and grants as we", "children": []}, {"name": "At Allergan, the focus on cutting-edge science, sound business practices and a global perspective co", "children": [{"name": "21", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}, {"name": "The Allergan Foundation receives hundreds of Community Grant applications each year, and thoughtful ", "children": []}, {"name": "Art4Kids", "children": []}, {"name": "provides art materials that are used in conjunction with therapy for children in shelters, hospitals", "children": []}, {"name": "Alzheimer\u2019s Family Services Center", "children": []}, {"name": "provides affordable access to high-quality, culturally-appropriate dementia healthcare and supportiv", "children": []}, {"name": "Heart of Texas Community Health Center", "children": []}, {"name": ", vulnerable pregnant women can obtain needed dental care; the", "children": []}, {"name": "Children\u2019s Burn Foundation", "children": []}, {"name": "provides medical, surgical and psycho-social treatment for child burn survivors locally, nationally ", "children": []}, {"name": "The Allergan International Foundation (AIF) continued the global extension of The Allergan Foundatio", "children": []}, {"name": "The AIF is active in the same four philanthropic areas: the arts, civic programs, education and heal", "children": []}, {"name": "For both TAF and AIF, grants are awarded to charitable organizations with high-quality programs and ", "children": []}, {"name": "Organizations that AIF is proud to be supporting include: The Westport Family & Community Resource C", "children": []}, {"name": "Leadership of The Allergan Foundation is headed up by Brent Saunders, President and Chief Executive ", "children": [{"name": "22", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}, {"name": "Additional Information", "children": [{"name": "The objectives and programs of the requesting organization must be clearly defined and reasonably ca", "children": []}, {"name": "TAF evaluates the impact to the community and the intended recipients of the donation or grant and i", "children": []}]}, {"name": "Grants generally are not approved for:", "children": [{"name": "Organizations that collect funds for redistribution to other nonprofit groups", "children": []}, {"name": "Regular, ongoing operating support", "children": []}, {"name": "Agencies, projects or programs primarily financed by government sources", "children": []}, {"name": "Promote education, research, and awareness of eye care, CNS, GI and Cystic Fibrosis, , dermatology, ", "children": []}, {"name": "Improve the quality of health care and patient access to care.", "children": []}, {"name": "Enhance and strengthen the communities where Allergan plc. has a facility or employees by contributi", "children": []}]}, {"name": "The Allergan Foundation will consider awarding grants for programs that:", "children": []}, {"name": "Grant Limitations", "children": [{"name": "Grants are not made to support or fund:", "children": [{"name": "Organizations that are not 501(c)(3) publicly supported charities", "children": []}, {"name": "Individual or family requests for scholarships, fellowship assistance, or other types of support", "children": []}, {"name": "Refugee- or religious-based activities for the purpose of furthering religious doctrine", "children": []}, {"name": "Fraternal, labor, or political organizations", "children": []}, {"name": "Organizations that discriminate on the basis of race, religion, creed, gender, or national origin", "children": []}, {"name": "Matching gifts", "children": []}, {"name": "University administrative, management, or indirect fees", "children": []}, {"name": "Golf tournaments, athletic events, league or team sponsorships, or school-affiliated orchestra, band", "children": []}, {"name": "Private schools K\u201312", "children": []}, {"name": "Fundraising acts or advertising sponsorships", "children": []}, {"name": "Activities that propagandize, influence legislation and/or elections; promote voter registration; po", "children": []}, {"name": "Institutions limiting their services to persons of a single religious sect or denomination", "children": []}, {"name": "Promotional exhibits, surveys, or consumer interest groups", "children": []}, {"name": "Endowments, capital, or building campaigns", "children": []}, {"name": "Contingencies, deficits, or debt reduction", "children": []}, {"name": "Charities or funds solely directed by a single physician or medical practice group", "children": [{"name": "23", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}, {"name": "going to have the greatest impact. Outcomes are measured periodically and randomly against the reque", "children": []}, {"name": "Allergan\u2019s reputation is measured qualitatively through periodic and random surveys with local commu", "children": []}, {"name": "\u201cWE CARE\u201d Grants", "children": [{"name": "The Allergan Foundation also evaluates requests for funding to organizations in which employees of A", "children": []}]}, {"name": "Product Donations", "children": [{"name": "In 2015, Allergan provided product donations to non-profit and relief organizations worldwide, total", "children": [{"name": "24", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}, {"name": "We will price our products in a way that is commensurate with, or lower than, the value they create ", "children": []}, {"name": "We will enhance access to patients. This means that Allergan will enhance our patient assistance pro", "children": []}, {"name": "We will work with policy makers and payers to facilitate better access to our medicines.", "children": []}, {"name": "We will not engage in price gouging actions or predatory pricing.", "children": []}, {"name": "We commit to providing an aggregate view of the net impact of price on our business at least annuall", "children": []}, {"name": "We will limit price increases. Where we increase price on our branded therapeutic medicines, we will", "children": []}, {"name": "We will not engage in the practice of taking major price increases without corresponding cost increa", "children": []}]}]}]}]}]}, {"name": "ACCESS TO MEDICINES \u2013 OUR SOCIAL CONTRACT", "children": [{"name": "Our biopharma industry is vital and has made profound contributions that have increased life expecta", "children": []}, {"name": "Allergan is committed to innovation, access, and responsible pricing ideals. This commitment is tran", "children": []}, {"name": "These are our commitments to the medical professionals and patients who count on us to continue find", "children": []}, {"name": "THE FOUR PRINCIPLES:", "children": [{"name": "1. Invest & Innovate 2. Access & Pricing 3. Quality & Safety 4. Education", "children": []}]}]}, {"name": "1.", "children": [{"name": "Invest & Innovate", "children": [{"name": "Our social contract begins where there is a patient with an unmet need. As we identify needs in our ", "children": []}, {"name": "That investment doesn\u2019t stop when a drug is first approved by a regulator. For many treatments, we i", "children": []}]}]}, {"name": "2.", "children": [{"name": "Access & Pricing", "children": [{"name": "We commit to making these branded therapeutic treatments accessible and affordable to patients while", "children": []}]}, {"name": "\u201cThe public\u2019s expectation is that we exist to heal and cure. It\u2019s an expectation that mirrors our ow", "children": [{"name": "25", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}]}, {"name": "3.", "children": [{"name": "Quality & Safety", "children": [{"name": "We commit to intensely monitoring the safety of our medicines, before they are approved by regulator", "children": []}]}]}, {"name": "4.", "children": [{"name": "Education", "children": [{"name": "We are committed to appropriately educating physicians about our medicines so that they can be used ", "children": [{"name": "25", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}, {"name": "Patient Resources Source \u2013 Allergan website", "children": [{"name": "At Allergan, we believe the best of medicine is realized when patients have the information they nee", "children": []}, {"name": "Since Allergan\u2019s inception, bringing the best of medicine to the forefront of patient care has alway", "children": []}, {"name": "For patients who cannot afford our medicines Allergan offers a patient assistance program (PAP) and ", "children": []}]}, {"name": "Physician Resources Source \u2013 Allergan website", "children": [{"name": "Underlying our commitment is a drive to help medical specialists improve patient outcomes. We pursue", "children": [{"name": "26", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}, {"name": "Allergan conducts research to understand the impact of our products on patient care in our disease a", "children": []}, {"name": "Allergan uses this research in our interactions with regulatory agencies such as the FDA and Ministr", "children": []}, {"name": "The majority of evidence generation at Allergan occurs in the following areas: Clinical Development ", "children": [{"name": "27", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}, {"name": "GHEOR works with cross-functional colleagues across Allergan\u2019s key therapeutic areas to generate the", "children": []}, {"name": "http:// www.clinicaltrials.gov/", "children": []}, {"name": ". These are being continually updated with the latest information.", "children": [{"name": "27", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}]}]}, {"name": "BIODIVERSITY", "children": [{"name": "Allergan has facilities and offices located in major cities and in rural locations. Allergan has est", "children": []}, {"name": "Allergan\u2019s corporate culture is steeped in a rich tradition of excellence, hard work, and a dedicati", "children": []}, {"name": "The work of our outstanding scientists and inventors is also recognized by their peers at our annual", "children": []}]}, {"name": "RECOGNIZING EXCELLENCE", "children": [{"name": "As we conclude our 2011\u20132015 Sustainability Strategic Cycle and transition to our 2020 Sustainaiblit", "children": [{"name": "28", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}]}, {"name": "SUSTAINABILITY PERFORMANCE SUMMARY TABLE", "children": [{"name": "1,2, 3, 4", "children": [{"name": "1. Data only for Manufacturing, R&D operations unless otherwise noted 2. 2010\u20132013 data only for leg", "children": [{"name": "SUSTAINABILITY PERFORMANCE INDICATOR 2010 2011 2012 2013 2014 2015\tSafety Management\tOccupational In", "children": [{"name": "29", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}]}]}, {"name": "Our Independence", "children": []}, {"name": "ERM CVS is a member of the ERM Group. This is the third year that ERM CVS has been engaged by Allerg", "children": []}]}, {"name": "REPORT ON THE VERIFICATION OF GHG EMISSIONS TO THE MANAGEMENT OF ALLERGAN, INC. -", "children": [{"name": "YEAR ENDING DECEMBER 31, 2015", "children": [{"name": "Verification Scope", "children": [{"name": "ERM Certification & Verification Services (ERM CVS) was commissioned by Allergan, Inc. (Allergan) to", "children": []}, {"name": "The assessment covered the following GHG accounting elements:", "children": []}, {"name": "Reporting Boundary;", "children": []}, {"name": "GHG Management System and Data Collection Processes;", "children": []}, {"name": "Data and GHG Emissions Quantification;", "children": []}, {"name": "Reporting Criteria; and", "children": []}, {"name": "Quality Assurance and Data Uncertainty", "children": []}, {"name": "This assurance engagement involved", "children": []}, {"name": "a review of consolidated group data at Allergan\u2019s office and R&D/ manufacturing facility in Irvine, ", "children": []}, {"name": "detailed review of data from manufacturing facilities, including site visits to review data at Aller", "children": []}, {"name": "Our work involved detailed review and substantiation of information through selected interrogation o", "children": []}, {"name": "Verification Objectives", "children": []}, {"name": "To determine the conformity of the GHG inventory with the reporting criteria.", "children": []}, {"name": "To assess completeness of the GHG inventory.", "children": []}, {"name": "To evaluate the GHG information system and its controls/management.", "children": []}, {"name": "To confirm whether the GHG assertion is without material discrepancy and whether the verification ac", "children": []}, {"name": "Greenhouse Gas Reporting Criteria", "children": []}, {"name": "GHG data has been reported based on the WRI/WBCSD GHG Protocol and the International Organization fo", "children": []}, {"name": "Greenhouse Gas Verification Criteria", "children": []}, {"name": "Verification activities were based on ISO 14064-3: Specification with guidance for the validation an", "children": []}, {"name": "Level of Assurance", "children": []}, {"name": "A reasonable level of assurance was applied during verification performance.", "children": []}, {"name": "Organizational Boundaries", "children": []}, {"name": "Allergan has consolidated its global GHG inventory according to the operational control approach, ex", "children": []}, {"name": "Assurance Conclusion", "children": []}, {"name": "Based on the approach described above, and the GHG reporting criteria applied, it is ERM CVS\u2019s opini", "children": []}, {"name": "Scope 1 Emissions:", "children": []}, {"name": "86,023 tonnes CO2-e", "children": []}, {"name": "Scope 2 Emissions (location-based):", "children": []}, {"name": "90,546 tonnes CO2-e", "children": []}, {"name": "Scope 2 Emissions (market-based):", "children": []}, {"name": "86,591 tonnes CO2-e", "children": []}, {"name": "Data and information supporting the GHG assertion were calculated based on measured as well as estim", "children": []}, {"name": "Observations", "children": []}, {"name": "Without compromising our conclusion above, we make the following observations:", "children": []}, {"name": "The overall data consolidation process would benefit from updating the GHG inventory management plan", "children": []}, {"name": "Allergan is exploring automating the process of incorporating invoice data into its GHG data managem", "children": []}, {"name": "Based on our work outlined above, we have provided Allergan with a separate, confidential GHG Verifi", "children": []}, {"name": "Limitations of Assurance Statement", "children": []}, {"name": "The findings presented here are not intended to be used as advice or as the basis for any decisions,", "children": []}, {"name": "Melanie Eddis, Partner 23 August 2016 ERM Certification and Verification Services, London www.ermcvs", "children": [{"name": "29", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}, {"name": "30", "children": [{"name": "2016 SUSTAINABILITY REPORT", "children": []}]}]}]}]}]}, {"name": "APPENDIX A: ALLERGAN FACILITIES INCLUDED IN THE GHG INVENTORY", "children": [{"name": "FACILITY NAME / NO. EMISSION SOURCE FACILITY TYPE LOCATION", "children": [{"name": "U.S. Administrative Headquarters", "children": []}]}]}]}]}]}]}